The Urologic Clinics of North America 1991: Vol 18 Index

15 Pages·1991·3.4 MB·English

Cumulative Index 1991
Volume 18
February ADVANCED PROSTATIC CARCINOMA, pages 1-173
May EVALUATION AND TREATMENT OF URINARY INCONTINENCE,
pages 175-419
August UROLOGIC ONCOLOGY, pages 421-601
November PARTIAL AND TOTAL BLADDER RECONSTRUCTION, pages
603-791
Note: Page numbers of issue and article titles are in boldface type.
Abdomen, examination of, for female urinary Androgen, production of. See Endocrine therapy.
incontinence, 201 Androgen ablation, total, for prostatic cancer. See Total
opening and packing of, in anatomic radical cystoprosta- androgen ablation.
tectomy, for bladder reconstruction, 668—669 Androgen receptor antagonists, for prostatic cancer, 9
prostatic cancer metastatic to, imaging of, 49-50 Angiomyolipomas, vs. incidental renal mass, 429
Acid-base disturbances, urinary diversion and, 728 Anterior exenteration. See Radical cystectomy.
Acidosis, hyperchloremic. See Hyperchloremic acidosis. Anti-androgens, for prostatic cancer. See Total androgen
Adenocarcinoma, in bladder reconstruction, intestinal ablation.
segments and. See Intestinal segments. after local failure, 496
of rectosigmoid colon, isolated ureterosigmoidostomy Antibodies, monoclonal. See Monoclonal antibodies.
and, 606-607 Anticholinergic agents, for painful bladder syndrome, 320
Adenomas, renal, vs. incidental renal mass, 428 to decrease bladder contractility, 269-271
Adrenal gland, androgen production in, 4-5 Anticlotting factors, effects of cyproterone acetate on,
Adrenal suppression, for prostatic cancer, 10 113-114
Adrenocorticotropin, and androgen production, 2 Antigen characterization, of new markers, for bladder
Adriamycin, for bladder tumors, 526-528 tumors, 511-512
for urologic sarcomas, 583, 587 Antigens, defined by monoclonal antibodies, in bladder
Alpha-adrenergic agonists, to increase outlet resistance, tumors, 519-521
276-277 Antihistamines, for painful bladder syndrome, 320
Alpha-sympathomimetic agents, for myelodysplastic Antral gastrocystoplasty, technique for, 652
urinary incontinence, 304-305 Appendicovesicostomy, Mitrofanoff principle in. See
Aminoglutethimide, for prostatic cancer, 10, 56 Mitrofanoff principle.
Amitriptyline, for painful bladder syndrome, 320 Artificial urinary sphincter, 375-381
Anandron, for prostatic cancer, 9, 58-60, 100. See also after bladder reconstruction, 677-686
Total androgen ablation. bladder cycle in, 682-683
Anatomic radical cystoprostatectomy, in bladder complications of, 680-681
reconstruction, 659-676 historical aspects of, 681
postoperative care of, 675 Mayo bladder design of, 681-682
preoperative preparation for, 659-660 placement site of, 678-679
technique for, 660-675 technique for, 679-680
division of puboprostatic ligaments and control of balloon pressure of, 376
dorsal vein, 670-672 complications of, surgical intervention for, 379-380
incision and exposure, 660-661 cuff implantation sites for, 375-376
mobilization of bladder from rectum, 669-670 cuff sizes for, 376
mobilization of prostate, 672-673, 675 for myelodysplastic urinary incontinence, 303-304
opening and packing of abdomen, 668-669 implantation of, evaluation of incontinence after, 376-
pelvic lymphadenectomy, 661, 663, 668 379
position, 660 endoscopy in, 377
transection of ureters and division of proximal vesi- history in, 377
cal pedicles, 669 pump examination in, 377
wide excision of neurovascular bundle, 675 radiography in, 377
778 Cumulative Index 1991
Artificial urinary sphincter (Continued) chronic urinary retention, 345-346
urodynamic tests in, 379 diagnosis and procedure selection in, 339-340
Atropine, to decrease bladder contractility, 269-270 immediate urinary incontinence, 344-345
Augmentation cystoplasty. See also Bladder late failures, 346-347
reconstruction; Kock pouch. nerve damage, 343
for myelodysplastic urinary incontinence, 301-303 osteitis pubis, 345
for painful bladder syndrome, 323 ureteral injuries, 342
urinary incontinence after, 383-388 wound complications, 345
anastomosis to urethra in, 387-388 patient evaluation for, 327-328
bowel segment physiology in, 383-384 physics of, 328-329
flap valve mechanism in, 386 results of, 334-336
hydraulic valves in, 386 techniques for, 329-334
ileal plication in, 385-386 abdominal approach, 330-331
intact segments in, 384 endoscopic vesical neck suspension, 331-332
intussuscepted nipple valve in, 384-385 needle bladder neck suspension, 332-334
Bladder-prostate rhabdomyosarcomas, in children, 577-
578
Bladder reconstruction. See also Augmentation
Bacilius Calmette-Guérin, for bladder tumors, 526—528 cystoplasty.
Back, examination of, for female urinary incontinence, 201 anatomic radical cystoprostatectomy in. See Anatomic
Baclofen, for myelodysplastic urinary incontinence, 305 radical cystoprostatectomy.
Bead-chain cystourethrography, of geriatric urinary artificial urinary sphincter after. See Artificial urinary
incontinence, 250 sphincter.
Benchekroun ileal valve, in bladder reconstruction, 717- Benchekroun ileal valve in. See Benchekroun ileal
724 valve.
complications of, 719-723 colonic neobladder in. See Colonic neobladder.
demographics of, 717 complications of, 755-764
postoperative care of, 718-719 intraoperative, 755-756
results of, 719 postoperative, 757-763
technique for, 717-718 bowel complications, 760
Benign prostatic hyperplasia, and male urinary calculi, 757
incontinence, 246 carcinoma, 761
Beta-adrenergic agonists, to decrease bladder contractility, catheterization, 757
274 femoral neuropathy, 762-763
Beta-adrenergic antagonists, to increase cutlet resistance, incontinence, 758-760
277 metabolic complications, 762. See also Intestinal
Bicarbonate, transport of, in intestinal tract, 726-727 segments.
Bile metabolism, in bladder reconstruction, intestinal reflux, 757
segments in, 746-747 renal complications, 762
Biopsy, of incidental renal mass, 433 spontaneous perforation, 760—761
of penile cancer, 161-162 preoperative, 755
of prostatic cancer, metastatic to spine, 154 gastric. See Gastric bladder reconstruction.
Bladder, complications of, in bladder reconstruction, 756— ileal neobladder in. See Ileal neobladder.
757 in children. See Urinary tract reconstruction.
decreasing contractility of, uropharmacology for. See isolated ureterosigmoidostomy in. See Isolated uretero-
Uropharmacology. sigmoidostomy.
dysfunction of, and male urinary incontinence, 233— Kock pouch in. See Kock pouch.
234, 236-237 through intestinal segments. See Intestinal segments.
injuries of, bladder neck suspension proceaures and, Bladder rhabdomyosarcomas, in children, 577-578
340-342 Bladder substitution. See Augmentation cystoplasty;
instability of, 345 Bladder reconstruction.
pediatric. See Pediatric urinary incontinence. Bladder training, for painful bladder syndrome, 318, 319
mobilization of, in anatomic radical cystoprostatectomy, Bladder tumors, combined modality therapy for, 547-554
for bladder reconstruction, 669-670 bladder preservation after, 549-550
overactive, clinical features of, 396 results of, 549
Bladder exstrophy, failed repair of, 687-699 subjects, materials, and methods for, 547-548
failed bladder neck reconstruction in, 691-696 survival after, 549-550
treatment of, 693-694 management of, molecular and immunologic, 515-524
failed closure in, 687-691 antigens defined by monoclonal antibodies, 519-
treatment of, 689-691 521
failed genital and urethral reconstruction in, 696-697 DNA and genetic alterations, 516-517
failure to gain capacity in, 691 oncogenes and suppressor genes, 517-518
Bladder neck suspension procedures, for female stress tumor cell products, 518
urinary incontinence, 327-337 monoclonal antibodies in. See Monoclonal antibodies.
complications of, 339-348 natural history of, 525-526
acute urinary retention, 343-344 neoadjuvant therapy for, 539-542
bladder injuries, 340-342 definition of response rate in, 540
bladder instability, 345 effect on T stage, 540
bleeding, 342-343 meaning of negative biopsy after, 540-541
Cumulative Index 1991 779
survival after, 541 Chloride, transport of, in intestinal tract, 726-727
new markers for, evaluation of, 509-513 Chlorpractin WCS 90, for painful bladder syndrome, 321
materials and methods for, 509-510 Chlorpromazine, for hyperchloremic acidosis, after gastric
results of, 510-512 bladder reconstruction, 650 :
radical cystectomy for. See Radical cystectomy. Cholelithiasis, bladder reconstruction and, 762
transitional-cell, CISCA chemotherapy for. See CISCA intestinal segments in, 749-750
chemotherapy. Cholesterol, and androgen production, 3
transurethral resection and intravesical therapy for. See Cholestyramine, for diarrhea, in bladder reconstruction,
Transurethral resection. 747
Bowel, complications of, bladder reconstruction and, 760 Chordee, correction of, after bladder exstrophy repair,
Bowel segments. See Intestinal segments. 696-697
Boyce-Vest procedure. See Isolated Circulatory arrest, hypothermic, for renal cell carcinoma,
ureterosigmoidostomy. with vena caval thrombi. See Vena caval thrombi.
Brachytherapy, iridium-192. See Iridium-i92 CISCA chemotherapy, for transitional-cell bladder
brachytherapy. tumors, 543-546
Brain, prostatic cancer metastatic to, imaging of, 52 materials and methods for, 543-544
Burch procedure. See Bladder neck suspension results of, 544
procedures. Colon conduits, in bladder reconstruction, metabolic
Buserelin, for prostatic cancer, with cyproterone acetate, consequences of, 730
116 Colonic neobladder, in bladder reconstruction, 609-614
Bypass, cardiopulmonary, for renal cell carcinoma, with advantages of, 612-613
vena caval thrombi. See Vena caval thrombi. patient selection for, 609
venovenous, in inferior vena cava. See Inferior vena postoperative care of, 612
cava. preoperative preparation for, 609
results of, 612
technique for, 610-611
Colonic reservoir, construction of, in colonic neobladder,
Caffeine, restriction of, for painful bladder syndrome, 320 610
Calcium antagonists, to decrease bladder contractility, Colostomy, diverting, in bladder reconstruction, 604—605
272-273 Colostomy function, after isolated ureterosigmoidostomy,
Calculi, formation of, bladder reconstruction and, 757 607
Cancer. See also Carcinoma. Computed tomography, of prostatic cancer, for primary
penile, penectomy for. See Penectomy. lesion, 36, 37
prostatic. See Prostatic cancer. for regional lymph nodes, 42
urinary tract. See Urinary tract cancer. for staging, 453-457
Carcinogenesis, bladder reconstruction and, 761 of Wilms’ tumor, 592
gastric, 651 Conduit diversion, in bladder reconstruction, metabolic
intestinal segments in. See Intestinal segments. consequences of, 729-731
Carcinoma. See also Cancer. Constipation, with pediatric urinary incontinence,
of exstrophic bladder-rectosigmoid rescrvoir, after iso- treatment of, 288-289
lated ureterosigmoidostomy, 607—608 Continence, urinary. See Urinary continence.
renal cell. See Renal cell carcinoma. Continent gastric reservoir, technique for, 654
transitional-cell, of bladder, radical cystectomy for. See Continent urinary diversion, Mitrofanoff principle in. See
Radical cystectomy. Mitrofanoff principle.
urethral, with urethral diverticula, 367 Corticosteroids, for painful bladder syndrome, 320
Cardiopulmonary bypass, for renal cell carcinoma, with for spinal cord compression, secondary to metastatic
vena caval thrombi. See Vena caval thrombi. prostatic cancer, 148
Casodex, for prostatic cancer, 9. See also Total androgen Credé maneuver, for myelodysplastic urinary
ablation. incontinence, 300, 303
clinical trials of, 103-108 Cyclic adenosine monophosphate, and androgen
_ phase I, 103 production, 2, 3
phase II, 103-107 Cyproterone acetate, for prostatic cancer, 10, 57, 99-100,
phase III, 107-108 111-122. See also Total androgen ablation.
preclinical studies of, 100-103 as adjuvant therapy, 118
Castration, for prostatic cancer, 7-9 as continuation therapy, for hormone-resistant dis-
Catheterization, complications of, bladder reconstruction ease, 117
and, 757 as first-line therapy, 114-117
intermittent, for myelodysplastic urinary incontinence, as intermittent therapy, 117-118
as neoadjuvant therapy, 118
Cellular enzymes, suramin binding to, 124-125 as second-line therapy, 117
Chemotherapy, CISCA. See CISCA chemotherapy. biologic effects of, 114
for bladder tumors, 526-528. See also Bladder tumors, effects of, on anticlotting factors and lipoprotein con-
combined modality therapy for. centrations, 113-114
with radical cystectomy, 531 on salt and water metabolism, 112
for nonseminomatous germ-cell testicular tumors, 565 on serum prolactin, 112
for prostatic cancer, 25-26 on serum testosterone, 112
for urologic sarcomas, 583, 587 on spermatogenesis, 112
for Wilms’ tumor, 595-596 for hot flushes, 118-119
Chest, prostatic cancer metastatic to, imaging of, 48-49 mechanism of action of, 111-112
780 Cumulative Index 1991
Cyproterone acetate (Continued) to decrease bladder contractility, 276
reversibility of, 114 Diverticula, urethral. See Urethral diverticula.
side effects of, 119 Diverticulectomy, urethral, for female urinary
under emergency conditions, 118 incontinence, with urethral diverticula, 369-372
Cystectomy, for painful bladder syndrome, 323 Diverting colostomy, in bladder reconstruction, 604-605
ileocolic neobladder after. See Ileocolic neobladder. DNA studies, of bladder tumors, 516
partial, for bladder rhabdomyosarcomas, in children, Dorsal vein, control of, in anatomic radical
577-578 cystoprostatectomy, for bladder reconstructio n, 670—
radical. See Radical cystectomy. 672
Cystoceles, and female urinary incontinence, 350-352 Doxepin, to decrease bladder contractility, 275
and patient selection, for bladder neck suspension pro- Doxorubicin, for bladder tumors, 526-528
cedures, 340 for urologic sarcomas, 583, 587
Cystography, of female stress urinary incontinence, 328
Cystometrography, filling, of male urinary incontinence,
232
of female urinary incontinence, 206-208 Electrical stimulation, for urinary incontinence, 393—407
Cystometry, bedside, of geriatric urinary incontinence, complications of, 402
251-252 electrical parameters in, 404
of urinary incontinence, equipment calibration in, 261, mixed stress and urge incontinence, 399-400, 402
263 myelodysplastic incontinence, 302
Cystoplasty, augmentation. See Augmentation cystoplasty. present position of, 404
Cystoprostatectomy, anatomic radical. See Anatomic pretreatment testing for, 402-403
radical cystoprostatectomy. stimulation modalities in, 403-404
Cystoscopy, of female urinary incontinence, with urethral stress incontinence, 397—400, 401—402
diverticula, 370 physiology of, 397-399
of painful bladder syndrome, 318-319 principles of stimulation, 399
Cystourethrography, bead-chain, of geriatric urinary results of, 401-402
incontinence, 250 urge incontinence, 393-397, 401
voiding. See Voiding cystourethrography. physiology of, 393-396
Cystourethroscopy, of female urinary incontinence, 205 principles of stimulation, 396-397
of male urinary incontinence, 231-232 results of, 401
Cysts, renal, vs. incidental renal mass, 429, 433 subtypes of, 396
Cytogenetic studies, of bladder tumors, 516-517 Electrolytes, transport of, in intestinal tract, 725-726
Cytotoxic therapy, for prostatic cancer, 25-26 Electromyography, of male urinary incontinence, 233
of myelodysplastic urinary incontinence, 297
of urinary incontinence, equipment calibration in, 264—
266
Dehydroepiandrosterone, and androgen production, 4 Elevation tests, for geriatric urinary incontinence, 249
Dehydroepiandrosterone sulfate, and androgen Endocrine therapy, for prostatic cancer, early vs. late, 15-
production, 4
Denervation procedures, for painful bladder syndrome, benefits of early therapy, 21-22
323 biology of prostatic cancer and, 17-19
Desmopressin, for pediatric nocturnal enuresis, 291—292 historical aspects of, 15-17
Detrusor dysfunction, and female urinary incontinence, results of clinical trials, 19—20
199 risks of early therapy, 20-21
and male urinary incontinence, 233-234, 236-237 failure of, stilbestrol diphosphate after. See Stilbestrol
and myelodysplastic urinary incontinence, 297-298, diphosphate.
300-303 physiologic basis of, 1-13
clinical features of, 396 adrenal suppression, 10
Devagination, of efferent limb, Benchekroun ileal valve agents with mixed mechanisms of action, 9-10
and, 723 androgen receptors in prostatic cancer, 7
Diarrhea, in bladder reconstruction, intestinal segments hormonal sensitivity and insensitivity of prostatic
in, 745-748 cancer, 5—7
Dicyclomine hydrochloride, to decrease bladder medical castration, 8-9
contractility, 271 normal regulation of androgen production, 1-5
Diethylstilbestrol, for prostatic cancer, 8 in adrenal gland, 4—5
vs. Casodex, 108 in anterior pituitary and, 1-3
with cyproterone acetate, 115-116 in prostatic cells, 5
with megestrol acetate, 84 in testes, 3-4
Digital rectal examination, to stage prostatic cancer, 453- pure anti-androgens, 9
457, 459-465 surgical castration, 7
accuracy of, 459-461 total androgen ablation. See Total androgen abla-
correlation with pathologic stage, 461-462 tion.
metastatic disease in, 462-463 for spinal cord compression, secondary to metastatic
patient prognosis in, 463-464 prostatic cancer, 149-150
vs. transrectal ultrasonography, 464 Endoscopy, of artificial urinary sphincter, 377
Dihydrotestosterone, and androgen production, 3, 4, 5, Enteroceles, and female urinary incontinence, 349-350,
93-94 352-353
Dimethylsulfoxide, for painful bladder syndrome, 321 Ephedrine, to increase outlet resistance, 276
Cumulative Index 1991 781
Epidermal growth factor, in bladder tumors, 518 features of stomach in, 651-652
in nonhormonal systemic therapy, for prostatic cancer, techniques for, 652-655
28, 29 antral gastrocystoplasty, 652
Estramustine phosphate, for prostatic cancer, 8 continent gastric reservoir and total bladder replace-
Estrogens, for prostatic cancer, 8 ment, 654-655
with megestrol acetate. See Megestrol acetate. wedge gastrocystoplasty, 652-654
to increase outlet resistance, 277-279 Gastrocystoplasty. See Gastric bladder reconstruction.
Exenteration, anterior. See Radical cystectomy. Genitourinary rhabdomyosarcomas, in children, 575-580
Exstrophy, bladder. See Bladder exstrophy. bladder and bladder-prostate, 577-578
External-beam irradiation, for nonseminomatous germ-cell gynecologic, 578-579
testicular tumors, 564-565 paratesticular, 575-577
Geriatric urinary incontinence, evaluation of, 243-256
algorithms in, 246-247
bead-chain cystourethrography in, 250
Fascial sling procedure, for myelodysplastic urinary bedside cystometry in, 251-252
incontinence, 304 elevation tests in, 249
Female urinary incontinence, bladder suspension history and symptoms in, 246
prcecedures for. See Bladder suspension procedures. intravenous urography in, 250-251
evaluation of, 197-209 laboratory tests in, 249-250
abdominal examination in, 201 neurologic examination in, 248
back and spine examination in, 201 pad weighing tests in, 244-245
classification by mechanism in, 198-199 pelvic examination in, 248
cystometrogram in, 206-208 pessary test in, 249
cystourethroscopy in, 205 postvoiding residual volume in, 249
definitions in, 197-198 Q-tip test in, 248-249
history in, 200-201 rectal examination in, 247-248
neurologic examination in, 201 stress tests in, 248
rectal examination in, 201, 204 ultrasonography in, 251
super urodynamics in, 208 Urilos system in, 245-246
urethral pressure profile in, 208 urodynamic tests in, 252-253
vaginal examination in, 204-205 voiding cystourethrography in, 251
vaginoscopy in, 205 voiding records in, 244
voiding cystourethrography in, 205-206 Glycopyrrolate, to decrease bladder contractility, 270
pelvic prolapse and. See Pelvic prolapse. Goserelin. See Zoladex.
urethral damage or loss and. See Urethral damage. Growth factors, in nonhormonal systemic therapy, for
with urethral diverticula. See Urethral diverticula. prostatic cancer, 27-29
Femoral neuropathy, bladder reconstruction and, 762-763 suramin binding to, 124—125
Fibroblast growth factor, in nonhormonal systemic Gynecologic rhabdomyosarcomas, in children, 578-579
therapy, for prostatic cancer, 28, 29
Filling cystometrography, of male urinary incontinence,
232
Finasteride, for prostatic cancer, 94, 95-96 Hautman ileal neobladder. See Augmentation cystoplasty.
Fistulas, urethrocutaneous, bladder exstrophy repair and, Hemibody irradiation, for prostatic cancer, 131-137
696 indications and rationale for, 131-132
urethrovaginal. See Urethrovaginal fistulas. results of, 133-135
valve, Benchekroun ileal valve and, 720-723 technique for, 132-133
Flavoxate hydrochloride, to decrease bladder contractility, toxicities of, 135-136
271-272 Hemorrhage, bladder neck suspension procedures and,
Fluid restriction, for painful bladder syndrome, 319 342-343
for pediatric urinary incontinence, 288 Heparin, for painful bladder syndrome, 320-321, 322
Fluoroscopy, of myelodysplastic urinary incontinence, 297 Heparin-binding growth factor, in nonhormonal systemic
Flurbiprofen, to decrease bladder contractility, 273 therapy, for prostatic cancer, 28
Flutamide, for prostatic cancer, 9, 57, 60, 100. See also Hepatic function, urinary diversion and, 728
Total androgen ablation. Hinman’s syndrome, clinical features of, 289
Follicle-stimulating hormone, and androgen production, 2 Hormone therapy, for prostatic cancer, after local failure,
Frankel grade system, of neurologic deficits, 155 496
Frozen sections, of pelvic lymph nodes, to stage prostatic Hot flushes, prostatic cancer and, cyproterone acetate for,
cancer, 451 118-119
Hydrodistention, for painful bladder syndrome, 322
Hydroureteronephrosis, after spinal cord injury. See
Spinal cord injury.
Gallstones, bladder reconstruction and, intestinal Hyoscyamine, for myelodysplastic urinary incontinence,
segments in, 749-750 300
Gastric bladder reconstruction, 649-657 Hyperchloremic acidosis, bladder reconstruction and, 762
complications of, 649-651 conduit diversions and, 729-731
carcinogenesis, 651 continent urinary diversion and, 731-732
metabolic disturbances, 649-650, 730-731 gastric bladder reconstruction and, 649-650
mucus production, 650 isolated ureterosigmoidostomy and, 606
nutritional disturbances, 650-651, 744 urinary diversion and, 727-728
782 Cumulative Index 1991
Hypothalamus, androgen production in, 1-3 of prostatic cancer, for remote organ involvement, 47—
Hypothermic circulatory arrest, for renal cell carcinoma, 48
with vena caval thrombi. See Vena caval thrombi. of Wilms’ tumor, 592
Hysterectomy, need for, with bladder neck suspension Intravesical therapy, and transurethral resection, for
procedures, 340 bladder tumors. See Transurethral resection.
for painful bladder syndrome, 321-322
Iridium-192 brachytherapy, for prostatic cancer, 481-483
after irradiation failure, 495
Ileal conduits, in bladder reconstruction, metabolic materials and methods for, 481—482
consequences of, 729-730 results of, 482-483
Ileal neobladder, in bladder reconstruction, 555-559, Irradiation. See also Radiotherapy.
623-630 external-beam, for nonseminomatous germ-cell testicu-
patient selection for, 625-626 lar tumors, 564-565
results of, 557-558, 626-628 for bladder tumors. See Bladder tumors, combined mo-
technique for, 555-557, 623-625 dality therapy for.
Ileocecal valve, in bladder reconstruction, nutritional for prostatic cancer, after surgical failure, 495-496
complications of, 745 local failure after, 488
Ileocolic neobladder, after cystectomy, 631-639 brachytherapy for, 495
complications of, 638 surgery for, 495
patient selection for, 631-632
for Wilms’ tumor, 595-596
postoperative care of, 634, 636, 638
hemibody. See Hemibody irradiation.
principles of, 631
Isolated ureterosigmoidostomy, in bladder reconstruction,
results of, 638
603-608
technique for, 632-634
patient selection for, 603-604
Ileum, in bladder reconstruction, nutritional complications
postoperative care of, 606-607
of, 745
preoperative preparation for, 604
Imipramine hydrochloride, for pediatric urinary
results of, 607-608
incontinence, 288
to decrease bladder contractility, 274-276 technique for, 604-606
to increase outlet resistance, 277
Immunosuppressive agenis, for painful bladder syndrome,
320
Immunotherapy, for bladder tumors, 523 Jejunal conduits, in bladder reconstruction, metabolic
Incontinence, urinary. See Urinary incontinence. consequences of, 730
Indiana pouch. See also Augmentation cystoplasty. Jejunum, in bladder reconstruction, nutritional
in children, 708-709 complications of, 744-745
Infections, wound, bladder neck suspension procedures
and, 345
Inferior vena cava, renal cell carcinoma in, 437-444
scope of problem, 437—438 Ketoconazole, for prostatic cancer, 9, 10, 56
venovenous bypass for, materials and methods for, Kidney function, after isolated ureterosigmoidostomy, 607
438-439 Kidney stones, bladder reconstruction and, intestinal
results of, 439-441 segments in, 750-751 ~
Intermittent catheterization, for myelodysplastic urinary Kidneys, complications of, after bladder reconstruction,
incontinence, 300 762
Intestinal segments, in bladder reconstruction, and in bladder reconstruction, 756
carcinogenesis, 737-742 Kock pouch. See also Augmentation cystoplasty.
clinical experience with, 737-738 in bladder reconstruction, 641-648
molecular basis of, 739-740 metabolic consequences of, 731-732
biochemical and histopathologic changes in, 738-739 patient selection for, 642
metabolic consequences of, 725-735, 762 postoperative care of, 644-645
in conduit diversions, 729-731 preoperative preparation for, 642
in continent urinary diversions, 731-732 technique for, 642-644
in ureterosigmoidostomy, 728-729 Kropp operation, for myelodysplastic urinary
pathophysiology of, 727-728 incontinence, 304
physiology of, 725-727
nutritional and gastrointestinal complications of, 743-
754
cholelithiasis, 749-750 Laboratory tests, for geriatric urinary incontinence, 249—
diarrhea and steatorrhea, 745-748 250
in large intestine, 745 Large intestine, in bladder reconstruction, nutritional
in small intestine, 744—745 complications of, 745
in stomach, 744 Laser therapy, for painful bladder syndrome, 323
urolithiasis, 750-751 Le Bag ileocolonic pouch. See Augmentation cystoplasty.
vitamin B12 deficiency, 748-749 Leong gastrocystoplasty, technique for, 652
Intestinocystoplasty. See Gastric bladder reconstruction. Leuprolide, for prostatic cancer, 8, 58-60
Intravenous urography, of geriatric urinary incontinence, Lipoproteins, effects of cyproterone acetate on, 113-114
250-251 Liver function, urinary diversion and, 728
of myelodysplastic urinary incontinence, 296 Luteinizing hormone, and androgen production, 2, 3
Cumulative Index 1991 783
Luteinizing hormone-releasing hormone, and androgen Mucus production, gastric bladder reconstruction and, 650
production, 2, 3 Musculotropic relaxants, to decrease bladder contractility,
Luteinizing hormone-releasing hormone agonists, for 271-272
prostatic cancer, 8-9, 56, 57 Myelodysplasia, and urinary incontinence, 295-308 -
with cyproterone acetate, 116 detrusor areflexia in, 303
Luteinizing hormone-releasing hormone analogues, for detrusor hyperreflexia in, 298, 300-302
prostatic cancer, vs. Casodex, 108 detrusor hypertonia in, 302-303
Lymphadenectomy, for renal cell carcinoma, 421-426 evaluation of, 295-296
anatomic boundaries in, 422 urodynamic tests in, 296-298
benefits of, 422-425 management of, 298
historical aspects of, 421-422 new therapies in, 305
lymphatic drainage in, 422 sphincteric insufficiency in, 303-305
morbidity of, 425
patient selection for, 425
pelvic, in anatomic radical cystoprostatectomy, for blad-
der reconstruction, 661, 663, 668 Neobladder, colonic. See Colonic neobladder.
in radical cystectomy, for bladder tumors, in women, ileal. See Ileal neobladder.
767-768 ileocolic. See Ileocolic neobladder.
retroperitoneal, for nonseminomatous germ-cell testicu-
Neodymium:YAG laser therapy, for painful bladder
lar tumors, 563-564, 568-571 syndrome, 323
for paratesticular rhabdomyosarcomas, in children,
Nephrectomy, partial, for incidental renal mass, 433-434
576
complications of, 435
to stage prostatic cancer, 450
total, for incidental renal mass, 434
Lymphography, of prostatic cancer, for regional lymph
Nephroblastoma. See Wilms’ tumor.
nodes, 43-44
Nerves, injuries of, bladder neck suspension procedures
and, 343
Neurologic examination, for female urinary incontinence,
201
Magnetic resonance imaging, of prostatic cancer, for
for geriatric urinary incontinence, 248
primary lesion, 36-37
Neuroprostheses, for myelodysplastic urinary
for regional lymph nodes, 41
for skeletal involvement, 47 incontinence, 305
for staging, 453-457 Neurostimulation, for painful bladder syndrome, 323-324
of spinal cord compression, secondary to metastatic Neurovascular bundle, wide excision of, in anatomic
prostatic cancer, 147 radical cystoprostatectomy, for bladder
Mainz pouch. See Augmentation cystoplasty. reconstruction, 675
Male urinary incontinence, radical prostatectomy and. See Nicotinic acid, for hyperchloremic acidosis, after gastric
Radical prostatectomy. bladder reconstruction, 650
Marshall-Marchetti-Krantz procedure. See Bladder Nilutamide. See Anandron.
suspension procedures. Nocturnal enuresis, pediatric. See Pediatric urinary
Martius labial fat pad graft, for urethrovaginal fistulas. See incontinence.
Urethrovaginal fistulas. Nonhormonal systemic therapy, for prostatic cancer, 25-
Mayo bladder, design of, 681-682 33
Megestrol acetate, for prostatic cancer, 57. See also Total cytotoxic therapy, 25-26
androgen ablation. growth factors in, 27-29
with low-dose estrogen, 83-91 oncogenes in, 29-31
effects of, on androgen action, 84, 88 stromal-epithelial interactions in, 26-27
on plasma hormones, 84 Non-neurogenic neurogenic bladder, pediatric, 289
with diethylstilbestrol, 84 Non-neurogenic voiding dysfunction, pediatric, 284
Methantheline, to decrease bladder contractility, 270-271 Nonsteroidal anti-inflammatory agents, for painful bladder
Micturition, ileal neobladder and, 628 syndrome, 320
Mitchell gastrocystoplasty, technique for, 652-654
Mitomycin C, for bladder tumors, 526-528
Mitrofanoff principle, of urinary continence, 386, 615-621
catheterizable channel in, alternatives for, 617 Oncocytomas, vs. incidental renal mass, 428-429
clinical experience with, 618-620 Oncogenes, in bladder tumors, 517-518
historical aspects of, 615-616 in nonhormonal systemic therapy, for prostatic cancer,
in children, 704 29-31
postoperative care of, 618 Orchiectomy, for prostatic cancer. See Total androgen
technique for, 616-617 ablation.
Mixed hemadsorption inhibition assay, of new markers, radical inguinal, for paratesticular rhabdomyosarcomas,
for bladder tumors, 510-511 in children, 576
Monoclonal antibodies, for bladder tumors, 521-523 Ornithine decarboxylase, in bladder reconstruction,
for detection and monitoring, 521-522 intestinal segments and, 738-739
for immunotherapy, 523 Osteitis pubis, bladder neck suspension procedures and,
for staging, 522-523 345
immunophenotype and prognosis, 521 Osteotomy, in exstrophy repair, 689-690
Mucin production, bladder reconstruction and, intestinal Outlet resistance, increasing, uropharmacology for. See
segments in, 738 Uropharmacology.
784 Cumulative Index 1991
Oxybutynin chloride, for myelodysplastic urinary biopsy in, 161-162
incontinence, 298, 300 partial, 162-164
for pediatric urinary incontinence, 287-288, 291 patient selection for, 161
to decrease bladder contractility, 271 postoperative care of, 168-169
total, 164-168
Pereyra procedure. See Bladder neck suspension
procedures.
Painful bladder syndrome, 317-325 Pessary test, for geriatric urinary incontinence, 249
clinical features of, 317-318 Phenylpropanolamine hydrochloride, to increase outlet
diagnosis of, 318-319 resistance, 276-277
treatment of, 319-322 Pinacidil, to decrease bladder contractility, 273
dietary measures in, 320-321 Pituitary gland, androgen production in, 1-3
intravesical, 321-322 Plain films, of artificial urinary sphincter, 377
surgical, 322-324 of prostatic cancer, for remote organ involvement, 48—
Paratesticular rhabdomyosarcomas, in children, 575-577 49
Pediatric urinary incontinence, 283-293 for skeletal involvement, 44
bladder instability and, treatment of, 287-289 of spinal cord compression, secondary to metastatic
fluid restriction in, 288 prostatic cancer, 147-148
for constipation, 288-289 Postvoiding residual volume, in geriatric urinary
pharmacologic, 287-288 incontinence, 249
timed voiding in, 289 Potassium-channel openers, to decrease bladder
development of urinary control and, 283-284 contractility, 273
evaluation of, 284-287 Pouch stones, Benchekroun ileal valve and, 723
history in, 284-285 Pressure-flow studies, of male uri~ary incontinence, 232
laboratory tests in, 286 Progestins, for prostatic cancer, 9--10
physical examination in, 286 Prolactin, and androgen production, 2
initial diagnosis of, further evaluation on basis of, 286— effects of cyproterone acetate on, 112
287 Propantheline bromide, for pediatric urinary
nocturnal, 289-292 incontinence, 288
evaluation of, 290-291 to decrease bladder contractility, 270
urodynamic tests in, 290 Propranolol, to increase outlet resistance, 277
treatment of, 290-291 Prostaglandin inhibitors, to decrease bladder contractility,
pharmacologic, 291-292 273-274
non-neurogenic neurogenic bladder and, 289 Prostate, mobilization of, in anatomic radical
non-neurogenic voiding dysfunction and, 284 cystoprostatectomy, for bladder reconstruction, 672-
vasopressin for, 279 673, 675
Pelvic dissection, in radical cystectomy, for bladder Prostate-specific antigen, to direct therapy for prostatic
tumors, in women, 768, 770 cancer, 494-495
Pelvic floor stimulation, for myelodysplastic urinary to stage prostatic cancer, 451-452
incontinence, 305 nodal status in, 467-471
Pelvic lymphadenectomy, in anatomic radical genesis of hypothesis for, 469-470
cystoprostatectomy, for bladder reconstruction, 661, implications for future research, 470
663, 668 materials and methods for, 467-468
in radical cystectomy, for bladder tumors, in women, results of, 468—469
767-768 Prostatectomy, radical. See Radical prostatectomy.
Pelvic prolapse, and female urinary incontinence, 349-353 Prostatic cancer, androgen receptors in, 7
cystoceles in, 350-352 combined modality therapy for, 477-480
enteroceles in, 349-350, 352-353 animal studies of, 478—479
rectoceles in, 349, 352 Mayo Clinic studies of, 478
total vaginal eversion in, 350 Memorial Sloan-Kettering studies of, 479
uterine prolapse in, 349 rationale for, 477-478
Pelvis, examination of, for geriatric urinary incontinence, uncontrolled clinical results of, 478
248 definitive treatment of, local failure after, 485-499
female, anatomy and physiology of, 175-195 after irradiation therapy, 488
arcus tendinaeus fascia pelvis, 183-184 after radical prostatectomy, 488-491
arcus tendinaeus musculi levator ani, 183-184 biopsy data on, 487
endopelvic fascia, 183-184 clinical data on, 487-488
genital hiatus and levator ani, 175-178 implications of, 496
intrinsic muscles of bladder and urethra, 191-193 materials and methods for, 485—486
levator ani degeneration, 193 treatment of, 491-496
pelvic cellular tissues, 191 endocrine therapy for. See Endocrine therapy.
perineal body, 189-191 hemibody irradiation for. See Hemibody irradiation.
pubourethral ligaments, 180-183 hormonal sensitivity and insensitivity of, 5-7
relation of bladder and urethra to vagina and cer- imaging of, 35-53
vix, 184-189 primary lesion, 35-41
space of Retzius, 178-180 computed tomography, 36, 37
upright posture and horizontal axis, 175 magnetic resonance imaging, 36-37
urogenital diaphragm, 189 ultrasonography, 35-36, 37, 41
Penectomy, for penile cancer, 161-169 regional lymph nodes, 41—44
Cumulative Index 1991 785
computed tomography, 42 Radical cystoprostatectomy, anatomic. See Anatomic
lymphography, 43-44 radical cystoprostatectomy.
magnetic resonance imaging, 41 Radical inguinal orchiectomy, for paratesticular
ultrasonography, 42-43 rhabdomyosarcomas, in children, 576
remote organ involvement, 47-52 Radical prostatectomy, 473-476
abdominal imaging, 49-50 and male urinary incontinence, 211-227, 229-241
brain imaging, 52 anatomy and physiology of, 229
chest radiography, 48-49 evaluation of, 231-233
intravenous urography, 47—48 cystourethroscopy in, 231-232
spinal imaging, 50, 52 electromyography in, 233
skeletal involvement, 44—47 filling cystometrography in, 232
magnetic resonance imaging, 47 pressure-flow studies in, 232
radiography, 44 retrograde urethrograpiiy in, 232
radionuclide scintigraphy, 44—47 urethral pressure profile in, 232-233
iridium-192 brachytherapy for. See Iridium-192 brachy- urodynamic tests in, 232
therapy. voiding cystourethrography in, 232
medical castration for, 8-9 historical aspects of, 212
nonhormonal systemic therapy for. See Nonhormonal incidence of, 229-231
systemic therapy. levator ani muscles in, 219-220
radical prostatectomy for. See Radical prostatectomy. normal sphincteric anatomy in, 212-219
spinal cord compression secondary to. See Spinal cord bladder neck and normal micturition, 213, 215
compression. continence zones, 213
staging of, 449-452 membranous urethra, 218-219
digital rectal examination in. See Digital rectal exami- prostate size and shape, 215-217
nation. striated muscle urethral sphincter, 217-218
frozen-section assessment in, 451 pathogenesis of, 233-236
imaging modalities in, 453-457 bladder dysfunction in, 233-234
patients and methods for, 453-454 obstruction in, 233
results of, 454-455 sphincter incompetence in, 234-235
lymphadenectomy in, 450 urodynamic data on, 235-236
prostate-specific antigen in. See Prostate-specific anti- prospective study of, 239-240
gen. sphincteric anatomy after, 220-224
seminal vesicles in, 452 condition of patient, 220-221
serum acid phosphatase in, 450-451 studies on, 221-222
systems for, 449 suture material and, 223-224
tumor volume vs. capsular penetration in, 452 type of anastomosis and, 224
whole-mount examination in, 451 vesical neck integrity, 222-223
surgical castration for, 7 vesical neck retubularization, 223
Prostatic cells, androgen production in, 5 treatment of, 236-238
Proximal vesical pedicles, division of, in anatomic radical for bladder dysfunction, 236-237
cystoprostatectomy, for bladder reconstruction, 669 for obstruction, 236
Puboprostatic ligaments, division of, in anatomic radical for sphincter incompetence, 237-238
cystoprostatectomy, for bladder reconstruction, 670- vs. continence, 224-225
672 local failure after, 488-491
Pubovaginal sling technique, for urethral damage, 356- materials and methods for, 473—474
357 results of, 474
Pyridium, for painful bladder syndrome, 320 Radiographs. See Plain films.
Radioimmunoassay, of new markers, for bladder tumors,
511
Radionuclide scintigraphy, of prostatic cancer, for skeletal
Q-tip test, for geriatric urinary incontinence, 248-249 involvement, 44—47
Radiotherapy. See also Irradiation.
for spinal cord compression, secondary to metastatic
prostatic cancer, 148
Radical cystectomy, for bladder tumors, 529-537 Rectal bladder. See Isolated ureterosigmoidostomy.
chemotherapy with, 531 Rectoceles, and female urinary incontinence, 349, 352
in women, 765-775 Rectosigmoid colon, adenocarcinoma of, isolated
complications of, 772-773 ureterosigmoidostomy and, 606—607
postoperative care of, 772-773 Rectum, examination of, for female urinary incontinence,
preoperative evaluation for, 765 201, 204
technique for, 766-772 for geriatric urinary incontinence, 247-248
anterior dissection, 770, 772 5a-Reductase inhibitors, for prostatic cancer, 9, 93-98.
initial exposure, 766—767 See also Total androgen ablation.
pelvic dissection, 768, 770 androgen effects on prostate, 93-94
pelvic lymphadenectomy, 767-768 as single-agent therapy, 96
vaginal dissection and completion of operation, clinical trials of, 95-96
772 disadvantages of, 97
materials and methods for, 530-531 in combination therapy, 96
results of, 531 mechanism of action of, 94-95
786 Cumulative Index 1991
5a-Reductase inhibitors (Continued) external spinal immobilization for, 155
preclinical studies of, 95 imaging of, 50, 52
prophylactic, 96-97 laboratory evaluation of, 154
Renal adenomas, vs. incidental renal mass, 428 mechanism of spread of, 153
Renal cell carcinoma, inferior vena caval involvement by. nonsurgical treatment of, 154-155
See Inferior vena cava. spinal reconstruction for, 156, 158
lymphadenectomy for. See Lymphadenectomy. Stamey procedure. See Bladder neck suspension
with vena caval thrombi. See Vena caval thrombi. procedures.
Renal cysts, vs. incidental renal mass, 429, 433 Steatorrhea, in bladder reconstruction, intestinal segments
Renal function, after isolated ureterosigmoidostomy, 607 in, 745-748
Renal mass, incidental, 427-436 Stenosis, stomal, Benchekroun ileal valve and, 719
differential diagnosis of, 428—433 Stilbestrol diphosphate, for prostatic cancer, after failed
incidence of, 427 endocrine therapy, 139-143
renal parenchyma preservation in, 434-435 cytotoxicity of, clinical evidence of, 140-141
treatment of, 433-434 experimental evidence of, 140
complications of, 435 treatment protocol for, 141-142
Renal parenchyma, preservation of, value of, 434-435 Stomach, in bladder reconstruction, nutritional
Retrograde urethrography, of male urinary incontinence, complications of, 744
232 Stones, formation of, bladder reconstruction and, 757
Retroperitoneal lymphadenectomy, for nonseminomatous Stress incontinence, electrical stimulation for. See
germ-cell testicular tumors, 563-564, 568-571 Electrical stimulation.
for paratesticular rhabdomyosarcomas, in children, 576 female, definition of, 198
Rhabdomyosarcomas, genitourinary. See Genitourinary Stress tests, for geriatric urinary incontinence, 248
rhabdomyosarcomas. Substitution cystoplasty. See Augmentation cystoplasty.
Suppressor genes, in bladder tumors, 517-518
Suramin, for prostatic cancer, 29, 123-129. See also Total
androgen ablation.
Salt metabolism, effects of cyproterone acetate on, 112 adrenocorticolytic properties of, 125-126
Sarcomas, urologic. See Urologic sarcomas. binding to growth factors and cellular enzymes, 124—
Scintigraphy, radionuclide, of prostatic cancer, for skeletal 125
involvement, 44—47 clinical trials of, 126-127
Seminal vesicles, invasion of, to stage prostatic cancer, in vitro effects of, 125
452 pharmacology of, 126
Serum acid phosphatase, to stage prostatic cancer, 450— toxicities of, 127-128
451
Silver nitrate, for painful bladder syndrome, 321-322
Small intestine, in bladder reconstruction, nutritional eeee
complications of, 744-745 Terbutaline, to decrease bladder contractility, 274
Sodium, transport of, in intestinal tract, 726 Terodiline, to decrease bladder contractility, 272-273
Sodium bicarbonate, for hyperchloremic acidosis, after Testes, androgen production in, 3-4
isolated ureterosigmoidostomy, 606 Testicular tumors, nonseminomatous germ-cell, 561-573
Sodium citrate, for hyperchloremic acidosis, after isolated chemotherapy for, 565
ureterosigmoidostomy, 606 external-beam irradiation for, 564-565
Sodium pentosanpolysulfate, for painful bladder natural history of, 561-563
syndrome, 321, 322 fertility considerations, 562-563
Spermatogenesis, effects of cyproterone acetate on, 112 patterns of dissemination, 561-562
Sphincter, artificial urinary. See Artificial urinary predictors of metastasis, 562
sphincter. retroperitoneal lymphadenectomy for, 563-564, 568—
Sphincter dysfunction, and female urinary incontinence, 571
199 surveillance for, 565-568
and male urinary incontinence, 234-235, 237-238 Testosterone, effects of cyproterone acetate on, 112
and myelodysplastic urinary incontinence, 297, 303-305 Testosterone-estradiol-binding globulin, and androgen
Spinal cord compression, secondary to metastatic prostatic production, 4
cancer, 145-152 Thiotepa, for bladder tumors, 526-528
diagnosis of, radiologic studies in, 147-148 Thrombi, vena caval. See Vena caval thrombi.
mechanism and clinical presentation of, 145-147 Timed voiding, for pediatric urinary incontinence, 289
treatment of, principles of, 148-149 Total androgen ablation, for prostatic cancer. See also
Spinal cord injury, hydroureteronephrosis after, 309-316 specific drugs, e.g., Anandron.
classification of, 309-311 American experience with, 55-63
diagnostic and therapeutic implications of, 315-316 historical aspects of, 55-56
pathophysiology of, 311-315 Canadian experience with, 75-82
Spine, examination of, for female urinary incontinence, best response to treatment in, 78
201 end-points for efficacy of, 77
prostatic cancer metastatic to, 153-159 entry characteristics in, 77
case report of, 158 patients and methods for, 76-77
causes of neurologic deficits in, 155-156 survival in, 79
classification of, 154 time to progression in, 78—79
clinical presentation of, 153-154 tolerance in, 79
diagnosis of, 154 European experience with, 65-73